These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8658104)

  • 41. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.
    Coppens HJ; Slooff CJ; Paans AM; Wiegman T; Vaalburg W; Korf J
    Biol Psychiatry; 1991 Apr; 29(7):629-34. PubMed ID: 1675892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The possible role of dopamine autoreceptors in neuroleptic atypicality.
    Javitt DC; Weinstein SL; Opler LA
    Psychiatr Dev; 1988; 6(1):57-71. PubMed ID: 2902622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel versus conventional antipsychotic drugs.
    Love RC
    Pharmacotherapy; 1996; 16(1 Pt 2):6-10. PubMed ID: 8778684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.
    Deutch AY; Moghaddam B; Innis RB; Krystal JH; Aghajanian GK; Bunney BS; Charney DS
    Schizophr Res; 1991; 4(2):121-56. PubMed ID: 1674882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of risperidone on positive features of schizophrenia.
    McEvoy JP
    J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.
    Singh AN; Barlas C; Saeedi H; Mishra RK
    J Psychiatry Neurosci; 2003 Jan; 28(1):39-47. PubMed ID: 12587849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
    Kane JM; Potkin SG; Daniel DG; Buckley PF
    J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards more effective antipsychotic treatment.
    Kane JM; Freeman HL
    Br J Psychiatry Suppl; 1994 Nov; (25):22-31. PubMed ID: 7865194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
    Borison RL
    Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ethical issues in drug selection for schizophrenia.
    Jeffries JJ
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S70-4. PubMed ID: 7504571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New antipsychotics in schizophrenia: the French experience.
    Vanelle JM; Olié JP; Lévy-Soussan P
    Acta Psychiatr Scand Suppl; 1994; 380():59-63. PubMed ID: 7914051
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Risperidone].
    Zolk O; Thürauf N
    Dtsch Med Wochenschr; 2003 Jun; 128(24):1353-6. PubMed ID: 12802745
    [No Abstract]   [Full Text] [Related]  

  • 56. Prospects for pharmacotherapy of schizophrenia.
    Pickar D
    Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875
    [No Abstract]   [Full Text] [Related]  

  • 57. [Aripiprazole in the treatment of schizophrenia].
    Bridler R
    Praxis (Bern 1994); 2005 Jun; 94(23):975-7. PubMed ID: 16001540
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
    Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
    J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.